Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients

被引:43
作者
de Boer, N. K. H. [1 ]
Zondervan, P. E. [3 ]
Gilissen, L. P. L. [4 ]
den Hartog, G. [5 ]
Westerveld, B. D. [6 ]
Derijks, L. J. J. [7 ]
Bloemena, E. [1 ]
Engels, L. G. J. B. [2 ]
van Bodegraven, A. A. [1 ]
Mulder, C. J. J. [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Gastroenterol & Hepatol, NL-1007 MB Amsterdam, Netherlands
[2] Massland Hosp, Sittard, Netherlands
[3] Erasmus MC, Rotterdam, Netherlands
[4] Univ Limburg, Acad Hosp Maastricht, Maastricht, Netherlands
[5] Rijnstate Hosp, Arnhem, Netherlands
[6] Isala Clin, Zwolle, Netherlands
[7] Max Med Ctr, Clin Pharm, Veldhoven, Neth Antilles
关键词
hepatotoxicity; inflammatory bowel disease; nodular regenerative hyperplasia; 6-thioguanine; 6-thioguaninenucleotides; TPMT;
D O I
10.1016/j.dld.2007.10.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. The use of 6-thioguanine has been proposed as a rescue drug for inflammatory bowel disease patients. Initial data on short-term efficacy and toxicity of 6-thioguanine were promising; however, these have been challenged by reports concerning its potential hepatotoxic effect (nodular regenerative hyperplasia). We proposed that these histological liver abnormalities may well be dose- or level-dependent. Aims. We performed a prospective multi-centre study on the hepatotoxic potential of long-term and (as compared with prior studies) low-dose 6-thioguanine use. Patients. Inflammatory bowel disease patients using 6-thioguanine for at least 30 consecutive months and consenting to undergo a liver biopsy were enrolled. Methods. Liver biopsy specimens were scored by two pathologists, unaware of clinical data. Laboratory parameters, determined prior to initiation of 6-thioguanine therapy and prior to biopsy, were reviewed. Results. Twenty-eight biopsies were analysed. The majority of patients (89%) were azathioprine and/or 6-mercaptopurine intolerant inflammatory bowel disease patients. In 26 patients (93%) no signs of nodular regenerative hyperplasia were detected; in two additional patients nodular regenerative hyperplasia could not be excluded due to inconclusive pathological findings. The mean 6-thioguanine dosage, 6-thioguaninenucleotides level, duration of use and cumulative dosage were 19.5 mg, 564 pmol/8 x 10(8) RBC, 38 months and 22491 mg, respectively. Conclusions. We have demonstrated that low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients is not likely to be associated with induction of nodular regenerative hyperplasia. The induction of nodular regenerative hyperplasia appears to be 6-thioguanine dose or 6-thioguaninenucleotides level dependent. (c) 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 19 条
[1]
Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations [J].
Al Hadithy, AFY ;
de Boer, NKH ;
Derijks, LJJ ;
Escher, JC ;
Mulder, CJJ ;
Brouwers, JRBJ .
DIGESTIVE AND LIVER DISEASE, 2005, 37 (04) :282-297
[2]
Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation [J].
Breen, DP ;
Marinaki, AM ;
Arenas, M ;
Hayes, PC .
LIVER TRANSPLANTATION, 2005, 11 (07) :826-833
[3]
On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients [J].
de Boer, Nanne K. H. ;
Derijks, Luc J. J. ;
Gilissen, Lennard P. L. ;
Hommes, Daniel W. ;
Engels, Leopold G. J. B. ;
de Boer, Sybrand Y. ;
den Hartog, Gijsbertus ;
Hooymans, Piet M. ;
Makelburg, Anja B. U. ;
Westerveld, Barend D. ;
Naber, Anton H. J. ;
Mulder, Chris J. J. ;
de Jong, Dirk J. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (35) :5540-5544
[4]
6-thioguanine treatment in inflammatory bowel disease:: A critical appraisal by a European 6-TG working party [J].
de Boer, NKH ;
Reinisch, W ;
Teml, A ;
van Bodegraven, AA ;
Schwab, M ;
Lukas, M ;
Ochsenkühn, T ;
Petritsch, W ;
Knoflach, P ;
Almer, S ;
van der Merwe, SW ;
Herrlinger, KR ;
Seiderer, J ;
Vogelsang, H ;
Mulder, CJJ .
DIGESTION, 2006, 73 (01) :25-31
[5]
Nodular regenerative hyperplasia and thiopurines: The case for level-dependent toxicity [J].
de Boer, NKH ;
Mulder, CJJ ;
van Bodegraven, AA .
LIVER TRANSPLANTATION, 2005, 11 (10) :1300-1301
[6]
Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia [J].
De Bruyne, R ;
Portmann, B ;
Samyn, M ;
Bansal, S ;
Knisely, A ;
Mieli-Vergani, G ;
Dhawan, A .
JOURNAL OF HEPATOLOGY, 2006, 44 (02) :407-410
[7]
de Jong D, 2001, GUT, V49, P874
[8]
Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy [J].
Derijks, LJJ ;
Gilissen, LPL ;
Engels, LGJB ;
Bos, LP ;
Bus, PJ ;
Lohman, JJHM ;
Curvers, WL ;
van Deventer, SJH ;
Hommes, DW ;
Hooymans, PM .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :311-318
[9]
6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment [J].
Derijks, LJJ ;
de Jong, DJ ;
Gilissen, LPL ;
Engels, LGJB ;
Hooymans, PM ;
Jansen, JBMJ ;
Mulder, CJJ .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (01) :63-67
[10]
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients [J].
Dubinsky, MC ;
Vasiliauskas, EA ;
Singh, H ;
Abreu, MT ;
Papadakis, KA ;
Tran, T ;
Martin, P ;
Vierling, JM ;
Geller, SA ;
Targan, SR ;
Poordad, FF .
GASTROENTEROLOGY, 2003, 125 (02) :298-303